Table 1.
Main characteristics of patient samples, comorbidities most frequently diagnosed during the baseline period, and description of index hospitalization
| Allo-HSCT | SOT | |||||||
|---|---|---|---|---|---|---|---|---|
| All patients n = 226 Ø PYs = 0.77 |
CMV n = 66 Ø PYs = 0.79 |
No CMV n = 160 Ø PYs = 0.77 |
p value | All patients n = 250 Ø PYs = 0.92 |
CMV n = 42 Ø PYs = 0.94 |
No CMV n = 208 Ø PYs = 0.92 |
p value | |
| Main characteristics | ||||||||
| Age in years, mean (SD) | 52.5 (16.1) | 54.1 (14.9) | 51.9 (16.5) | 0.320 | 53.0 (13.1) | 54.6 (13.2) | 53.7 (13.4) | 0.430 |
| Female patients, n (%) | 94 (41.6) | 30 (45.4) | 64 (40.0) | 0.462 | 91 (36.4) | 14 (33.3) | 77 (37.0) | 0.727 |
| CCIa, mean (SD) | 4.2 (2.8) | 4.3 (2.6) | 4.2 (2.9) | 0.667 | 4.6 (2.3) | 5.0 (2.5) | 4.5 (2.3) | 0.242 |
| Ten most frequently diagnosed comorbidities (including ICD-10-GM code), n (%) | ||||||||
| I10.- Essential (primary) hypertension | 114 (50.4) | 34 (51.5) | 80 (50.0) | 0.884 | 203 (81.2) | 36 (85.7) | 167 (80.3) | 0.519 |
| D69.- Purpura and other hemorrhagic conditionsb | – | – | – | – | 35 (14.0) | 10 (23.8) | 25 (12.0) | 0.053 |
| D70.- Agranulocytosisb | – | – | – | – | 4 (1.6) | 1 (2.4) | 3 (1.4) | 0.523 |
| E78.- Disorders of lipoprotein metabolism and other lipidemias | 54 (23.9) | 15 (22.7) | 39 (24.4) | 0.865 | 109 (43.6) | 22 (52.4) | 87 (41.8) | 0.234 |
| M54.- Dorsalgia | 97 (42.9) | 35 (53.0) | 62 (38.8) | 0.055 | 62 (24.8) | 11 (26.2) | 51 (24.5) | 0.846 |
| D61.- Other aplastic anemiasb | – | – | – | – | 8 (3.2) | 1 (2.4) | 7 (3.4) | 1.000 |
| D64.- Other anemiasb | – | – | – | – | 70 (28.0) | 14 (33.3) | 56 (26.9) | 0.452 |
| E79.- Disorders of purine and pyrimidine metabolism | 49 (21.7) | 18 (27.3) | 31 (19.4) | 0.215 | 77 (30.8) | 14 (33.3) | 63 (30.3) | 0.716 |
| K29.- Gastritis and duodenitis | 39 (17.3) | 13 (19.7) | 26 (16.3) | 0.564 | 86 (34.4) | 15 (35.7) | 71 (34.1) | 0.860 |
| K76.- Other diseases of liver | 50 (22.1) | 16 (24.2) | 34 (21.3) | 0.371 | 70 (28.0) | 13 (31.0) | 57 (27.4) | 0.707 |
| Index hospitalization | ||||||||
| LOS, mean (SD) | 42.8 (22.4) | 45.1 (20.3) | 41.0 (23.3) | 0.173 | 45.9 (58.7) | 43.9 (37.3) | 46.3 (62.2) | 0.207 |
| CMV diagnosis, n (%) | 35 (15.5) | 35 (53.0) | NA | – | 13 (5.2) | 13 (31.0) | NA | – |
| Death, n (%) | 24 (10.6) | 4 (6.1) | 20 (12.5) | 0.234 | 18 (7.2) | 2 (4.8) | 16 (7.7) | 0.746 |
Allo-HSCT allogeneic hematopoietic stem cell transplantation, CMV cytomegalovirus, NA not applicable, PY patient-year, SD standard deviation, SOT solid organ transplantation
aCharlson comorbidity index, not adjusted for age
bDiagnoses generally present in HSCT patients not shown for respective patient group